…D patients were six-fold more likely to have a poor outcome compared to non-comorbid patients. RIS: stratifying risk of progression An analysis of the RelevarEM MS/NMOSD registry in Argentina (n=88) reported that patients with radiologically isolated syndrome with two or three risk factors were at high risk of progression to CIS/MS (Rojas et al. ECTRIMS 2021; abstracts P006 and P009). Over the 40-month follow-up period, 44.3% showed a new MRI lesi…

…n=111). Results: Mean annualized relapse rate was 0.20; 72-73% were relapse-free 82-90% of patients did not have sustained EDSS worsening by week 192. Conclusion: Long-term efficacy of satralizumab appears to be sustained. P032 – COVID-19 in neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody disease patients in North America; COViMS registry S.D. Newsome et al. Objective: To determine COVID-19 outcomes in pati…